755 related articles for article (PubMed ID: 22473716)
1. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
3. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
8. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
9. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.
Kwiatt ME; Patel MS; Ross SE; Lachant MT; MacNew HG; Ochsner MG; Norwood SH; Speier L; Kozar R; Gerber JA; Rowell S; Krishnakumar S; Livingston DH; Manis G; Haan JM
J Trauma Acute Care Surg; 2012 Sep; 73(3):625-8. PubMed ID: 22929493
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
11. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
12. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
[TBL] [Abstract][Full Text] [Related]
13. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
[TBL] [Abstract][Full Text] [Related]
14. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular weight vs. unfractionated heparin for prevention of venous thromboembolism in general surgery: a meta-analysis.
Nair P; Trivedi R; Hu P; Zhang Y; Merchant AM
Updates Surg; 2021 Feb; 73(1):75-83. PubMed ID: 32880870
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review of Safety and Cost-Effectiveness of Venous Thromboembolism Prophylaxis Strategies in Patients Undergoing Craniotomy for Brain Tumor.
Algattas H; Damania D; DeAndrea-Lazarus I; Kimmell KT; Marko NF; Walter KA; Vates GE; Jahromi BS
Neurosurgery; 2018 Feb; 82(2):142-154. PubMed ID: 28402497
[TBL] [Abstract][Full Text] [Related]
17. Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry.
Puymirat É; Aissaoui N; Silvain J; Bonello L; Cuisset T; Motreff P; Bataille V; Durand E; Cottin Y; Simon T; Danchin N;
Arch Cardiovasc Dis; 2012; 105(6-7):347-54. PubMed ID: 22800719
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
Marciniak CM; Kaplan J; Welty L; Chen D
PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Kahale LA; Matar CF; Hakoum MB; Tsolakian IG; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD006649. PubMed ID: 34878173
[TBL] [Abstract][Full Text] [Related]
20. Differences between low-molecular-weight and unfractionated heparin for venous thromboembolism prevention following ischemic stroke: a metaanalysis.
Shorr AF; Jackson WL; Sherner JH; Moores LK
Chest; 2008 Jan; 133(1):149-55. PubMed ID: 17925410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
